JC06 Rec'd PCT/PTO 12 SI

IN THE UNITED STATES PATENT AND TRADEMARK OFF

Applicants:

LINUS S. LIN et al.

Serial No. # 10/538,395

June 9, 2005

For: SUBSTITUTED AMIDES



Art Unit:	 	
Examiner:		

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

Date __ 9/9 /2001

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited
by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120
are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION				
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			

If this is inconvenient, add	ditional copies will be submitted upon reque	st.	
6. In accordance with	37 C.F.R. 1.97, (check one)		
the attached informat	ion is filed within three months of the filing d	ate of the captioned case.	
the attached informat Office Action on the n	ion is filed more than three months after the nerits.	filing date but prior to the m	ailing of a first
Office Action on the n	ion is being filed more than three months aft nerits, but before the mailing date of a Final fore given to charge Deposit Account No. 13	Action or Notice of Allowand	ce. The enclosed
the undersigned certicited in any communi	fies that each item of information contained cation from a foreign patent office in a counting of this Statement.		
a communication from person signing the ce	fies that no item of information contained in n a foreign patent office in a counterpart fore rtification after making reasonable inquiry, w han three months prior to the filing of this St	eign application, and, to the was known to any individual	knowledge of the
		Respectfully submitted,	
		By: CATHERINE D. FITC	Oru_
		Attorney For Appl	icant(s)
		Reg. No. <u>36,502</u>	
		MERCK & CO., INC. Patent Dept., RY60-30	
		P.O. Box 2000	
		Rahway, N.J. 07065-0907	•
		(732)594- <u>4283</u>	
		Date: September 9, 2005	

		<u> </u>			Patent and Tradentalk Office; 0.3 DEPARTMENT OF COMMERCE		
s	Substitute for form 1449A/PTO			COMPLETE IF KNOWN			
]	NFORMATION	DIS	CLOSURE	Application Number	10/538,395		
	STATEMENT BY	7 A TO	DI ICANT	Filing Date	June 9, 2005		
	OIAIEMENI DI	AP	PLICANI	First Named Inventor	Linus S. Lin et al.		
			,	Group Art Unit			
	(use as many sheet	s as n	ecessary)	Examiner Name			
Sheet	1	of	4	Attorney Docket Number	21261P		

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
		6344474		MARUANI et al.	02/05/2002			
		2005/0154202		FONG et al.	08/04/2005			
		2005/0182103		FINKE et al.	08/18/2005			
		2004/0248956		HAGMANN et al.	12/09/2004			
		2003/0114495		FINKE et al.	06/19/2003			
		2004/0058820		HAGMANN et al.	03/25/2004			
		2004/0224962		COE et al.	11/11/2004			
		6359175		PHILIPPE et al.	03/19/2002			
		2004/0224963		COE et al.	11/11/2004			
		2005/0171161		FONG et al.	08/04/2005			
		2005/0137159		BAB et al.	06/23/2005			
		1,000,000,000,000,000						

	FOREIGN PATENT DOCUMENTS								
			Foreign Patent Document		N C. Dava	Date of Publication of			
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
			WO 98/33765 •		E.I. DuPont De Nemours and Company	08/06/1998			
			WO 98/56754 -		L'Oreal	12/17/1998			
			WO 2004/012671 ·		Merck & Co., Inc.	02/12/2004			
			WO 2005/020988 1		Solvay Pharmceuticals GMBH	03/10/2005			
			WO 2005/020992		Solvay Pharmceuticals GMBH	03/10/2005			
			WO 2005/027837 ·		Merck & Co., Inc.	03/31/2005			
			WO 2005/043327 ,		Docomo Communications Laboratories USA, Inc.	05/12/2005			
			WO 2004/048317-		Merck & Co., Inc.	06/10/2004			
			WO 2005/000301 ·		F. Hoffmann-La Roche AG	01/06/2005			
			WO 2005/000809		Merck & Co., Inc.	01/06/2005			

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2005

	•			Falent and Tradellark Office; U.S DEPARTMENT OF COMMERCE	
Substitute for form 1449A/PTO		COMPLETE IF KNOWN			
NFORMATION :	DIS	CLOSURE	Application Number	10/538,395	
TATENATENTE DS/	A TO	DI ICANT	Filing Date	June 9, 2005	
IAIEMENI DI	AP.	PLICANI	First Named Inventor	Linus s. Lin et al.	
		,	Group Art Unit		
(use as many sheets	as n	ecessary)	Examiner Name		
2	of	4	Attorney Docket Number	21261P	
	NFORMATION TATEMENT BY	NFORMATION DISC TATEMENT BY AP (use as many sheets as n	TATEMENT BY APPLICANT (use as many sheets as necessary)	NFORMATION DISCLOSURE TATEMENT BY APPLICANT (use as many sheets as necessary) Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Docume Number	Name of Patentee or Applicant C		Date of Publication of Cited Document			
midais	110.		(if known)	or entre potential	MM-DD-YYYY			

				1 1 174 - 184 - 184				

				, , , ,				
-								

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Office Number Code		Kind Name of		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		wo:	2005/009479		Merck & Co., Inc.	02/03/2005	
		woo	03/009005		Westerngeco Seismic Holdings Limited	01/30/2005	
		woo	03/007887		Merck & Co., Inc.	01/30/2003	
		woo	01/58450		Sanofi-Synthelabo	08/16/2001	
		woo	01/09120		Ortho-McNeil Pharmaceutical, Inc.	02/08/2001	
		woo	03/063781		Merck & Co., Inc.	08/07/2003	
		woo	03/075660		Merck & Co., Inc.	09/18/2003	
		woo	03/077847		Merck & Co., Inc.	09/25/2003	
		wo :	2003/082256		Sanofi-Synthelabo	10/09/2003	
		woo	03/087037		Merck & Co., Inc.	10/23/2003	

Examiner Signature			Date Considered	·

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005)

Su	bstitute for form 1449A/PTO	•		Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN			
	NFORMATION	N DISC	CLOSURE	Application Number	10/538,395		
C		X 7 A 1 01	DI ICANIT	Filing Date	June 9, 2005		
5	TATEMENT B	YAPI	PLICANI	First Named Inventor	Linus S. Lin et al.		
			,	Group Art Unit			
	(use as many shee	ets as ne	ecessary)	Examiner Name			
Sheet	3	of	4	Attorney Docket Number	21261P		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY	
	-					
					· · · · · ·	
					A A A A A A A A A A A A A A A A A A A	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication of
Initials*		Office		Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
			WO 2005/039550 -		Solvay Pharmaceuticals GMBH	05/06/2005
:			WO 03/082833 、		Consejo Superior De Investigaciones Cientificas & Unversidad Rey Juan Carlos	10/09/2003
			WO 03/086288.		Merck & Co., Inc.	10/23/2003
			WO 04/029204		Merck & Co., Inc.	04/08/2004
					,	

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 14498/PTO			COMPLETE IF KNOWN			
	DIS	CLOSURE	Application Number	10/538,395		
יים אינו אינו אינו אינו אינו אינו אינו אינו	7 A TO		Filing Date	June 9, 2005		
IAIEWIENI DI	Ar	PLICANI	First Named Inventor	Linus S. Lin et al.		
		,	Group Art Unit			
(use as many sheets	s as n	ecessary)	Examiner Name			
4	of	4	Attorney Docket Number	21261P		
	TATEMENT BY	NFORMATION DIS TATEMENT BY AP (use as many sheets as n	NFORMATION DISCLOSURE TATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number Filing Date First Named Inventor (use as many sheets as necessary) Figure 1449B/PTO Application Number Filing Date First Named Inventor Group Art Unit Examiner Name		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Lange et al., Drug Discovery Today, Vol. 10 (2005), pp. 693-702, "Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists",
	AB	Petitet et al., Emerging Drugs, Vol. 3 (1998), pp. 39-53, "The therapeutic applications of cannabinoid agonists and antagonists"
	AC	Di Marzo et al., Emerging Therapeutic Targets, Vol. 5 (2001), pp. 241-265, "Endocannabinoids Part I: Molecular basis fo endocannabinoid formation, action and inactivation and development of selectie inhibitors"
	AD	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
	AE	Adam et al., Exp. Opin. Ther. Patents, Vol. 12 2002), pp. 1475-1489, "Recent advances in the cannabinoids"
	AF	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
	AG	Ito et al., Chem. Pharm. Bull., Vol. 20 (1972), pp. 1762-1767, "Catalytic hydrogenation of tetrahydro-4H-1,3-oxazin-4-ones and 4-oxazolidinones"
	АН	Ishiwata et al., Yakugaku Zashi, Vol. 71 (1951), pp. 1272-1274, "Studies on the syntheses of isoquinoline derivatives"
	AI	Grundy et al., Exp. Opin. Investig. Drugs, Vol. 11 (2002), pp. 1365-1374, "The therapeutic potential of the cannabinoids in neuroprotection"
	AJ	Pines et al., J. Med. Chem., Vol. 10 (1967), pp. 725-728, "The stereochemistry of 2,3-diphenyl-1-methylpropylamine"
	AK	Schultz et al., J. Med. Chem., Vol. 10 (1967), pp. 717-724, "Maleamic acids that affect plasma cholesterol and penicillin excretion"
	AL	Le Foll et al., J. Pharmacol. Exp. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005)